Lifestyle Medicine and Migraine in Viet Nam: Sleep Regularity, Medication-Overuse Risk, and Preventive Treatment

Lifestyle Medicine and Migraine in Viet Nam: Sleep Regularity, Medication-Overuse Risk, and Preventive Treatment

Primary category: Evidence & Clinical Practice
Secondary category: Lifestyle Medicine in Viet Nam
Article type: VLMA Perspective
Last reviewed: October 30, 2026

A person living with migraine notices that headaches seem to become more frequent after several nights of irregular sleep. They try going to bed earlier, avoiding foods they suspect might trigger attacks, and taking pain medication whenever a headache starts. Some of these changes may help, but months later, the headaches remain frequent, medication use has increased, and ordinary activities are still difficult.

At this point, the problem may involve more than sleep habits or stress. The person may need more effective treatment for individual attacks, preventive migraine therapy, or assessment for medication-overuse headache.

This distinction is important for Lifestyle Medicine. Healthy routines can support migraine management, but migraine is a neurological disorder, not simply a consequence of unhealthy habits. Effective care requires appropriate diagnosis, safe medication use, attention to individual circumstances, and recognition of when lifestyle interventions alone are insufficient.

Several developments in 2026 make this discussion particularly relevant. In August, the American Academy of Neurology and the American Headache Society published updated recommendations for pharmacological migraine prevention in adults. A study published in September examined the relationship between sleep duration and migraine burden, while the International Headache Society published recommendations on structured headache history-taking in October.

In Viet Nam, the Ministry of Health also issued professional guidance in August 2026 that includes migraine within the diagnosis and treatment of diseases using traditional medicine and the integration of traditional and modern medicine.

Together, these developments offer an opportunity to examine how evidence-based Lifestyle Medicine can complement established migraine care without overstating what lifestyle changes can achieve or delaying necessary medical treatment.

Migraine Is More Than a Recurrent Headache

Migraine is a neurological disorder characterized by recurrent attacks that may involve moderate or severe headache, nausea, sensitivity to light and sound, and substantial interference with daily activities. Some people experience migraine with aura, involving temporary neurological symptoms such as visual or sensory disturbances, while others have migraine without aura.

The experience often extends beyond the headache itself. Fatigue, difficulty concentrating, neck discomfort, food cravings, or changes in mood may occur before an attack. Exhaustion and cognitive difficulties can also persist after the headache has improved.

These features matter because migraine is sometimes approached as an ordinary headache that should respond to rest, hydration, or a readily available pain reliever. For someone experiencing frequent or disabling attacks, that approach may leave an important part of the condition untreated.

Migraine is diagnosed primarily through clinical history and examination, using established diagnostic criteria such as the International Classification of Headache Disorders, Third Edition. Assessment should consider attack frequency, duration, associated symptoms, functional impact, previous treatment response, medication use, and any features suggesting a secondary cause.

The importance of careful history-taking was reinforced by the International Headache Society Education Committee in a paper published in Cephalalgia Reports on October 21, 2026. The authors emphasized structured, patient-centered communication to improve understanding of headache patterns, disability, medication use, and clinically important warning signs.

This is particularly relevant when patients describe their condition mainly in terms of severe attacks. They may underestimate the total number of headache days, forget milder episodes, or not recognize how frequently medication has been used. A consultation focused only on pain intensity may miss these details.

Not every recurrent headache is migraine, and an established migraine diagnosis does not exclude the possibility of another condition developing later. A headache that reaches maximum intensity suddenly, new neurological deficits, altered consciousness, fever with concerning symptoms, or a substantial change in headache pattern may require urgent medical evaluation rather than another attempt at lifestyle management.

Understanding the headache pattern and recognizing when further investigation is necessary remain essential parts of safe care.

Why Sleep Regularity Matters in Migraine

Sleep and migraine are closely connected, although the relationship is more complicated than simply saying that insufficient sleep causes headaches.

People with migraine frequently report irregular sleep schedules, insufficient sleep, poor sleep quality, or insomnia. For some individuals, substantial changes in sleep timing or duration appear to be associated with attacks.

At the same time, migraine itself can disturb sleep. Symptoms that develop before an attack, including fatigue or changes in alertness, may influence how a person sleeps. A poor night's sleep followed by migraine therefore does not necessarily establish that the sleep disturbance caused the attack.

A study published in Headache on September 28, 2026, examined self-reported sleep duration among 6,267 adults with migraine participating in the United States Headache Assessment via a Digital Platform study.

Compared with participants reporting seven to nine hours of sleep, those reporting six hours or less, as well as those reporting ten hours or more, had more monthly headache days and greater migraine-related disability. Perceived stress statistically accounted for part of the observed associations.

These findings add to the evidence connecting sleep characteristics with migraine burden. However, the study was cross-sectional, relied on self-reported information, and recruited participants through a digital migraine platform. It cannot establish that shorter or longer sleep caused more migraine attacks, nor does it demonstrate that changing sleep duration alone will improve migraine outcomes.

Longer reported sleep may also reflect underlying health conditions, greater symptom burden, recovery needs, or other factors that cannot be fully separated in this type of research.

Nevertheless, maintaining reasonably consistent sleep and wake times remains a practical component of migraine management, particularly for people who notice an association between disrupted routines and attacks.

The objective should not be perfect sleep. An inflexible bedtime or excessive concern about obtaining an ideal number of hours may become another source of stress. A more useful approach is to support adequate sleep opportunity and a sustainable routine that fits the individual's circumstances.

This is particularly important for shift workers, healthcare professionals, parents caring for young children, and people with unpredictable schedules. They may have limited control over sleep timing, making realistic adjustments more appropriate than recommendations they cannot consistently follow.

Persistent insomnia, excessive daytime sleepiness, loud snoring, witnessed breathing pauses, or other symptoms suggesting a sleep disorder should also be evaluated when clinically indicated. Such conditions deserve appropriate assessment rather than being attributed automatically to migraine.

Lifestyle Support Should Not Become an Endless List of Triggers to Avoid

People with migraine are often advised to identify and avoid triggers. These may include particular foods, caffeine, missed meals, changes in sleep, physical exertion, stress, or environmental exposures.

Some of these factors may be relevant to particular individuals. However, a universal list of prohibited foods and activities is unlikely to be appropriate for everyone.

The relationship between potential triggers and migraine is individualized, and identifying a true trigger is not always straightforward.

For example, someone may crave chocolate before developing a migraine attack and conclude that eating chocolate caused the headache. Yet food cravings can occur during the premonitory phase of migraine, before pain begins. What appears to be a trigger may sometimes be an early symptom of the attack itself.

Fatigue, altered mood, and other premonitory symptoms can create similar difficulties in interpretation. This is one reason to favor careful observation over extensive elimination diets.

Regular meals, adequate hydration, and a nutritionally balanced eating pattern can support general health and may help people whose attacks appear associated with missed meals or substantial dietary changes. However, there is no single dietary pattern proven to prevent migraine for everyone.

Routine exclusion of numerous foods may create unnecessary restrictions, nutritional concerns, and additional anxiety without clear evidence of benefit.

Caffeine requires a similarly balanced approach. Excessive intake, irregular consumption, and abrupt withdrawal may contribute to headaches in some individuals. Someone who regularly consumes caffeine may experience withdrawal-related headache after suddenly stopping. Gradual, individualized adjustments may therefore be more appropriate than advising every person with migraine to eliminate caffeine immediately.

Physical activity can also contribute to migraine management. Regular, manageable exercise may support sleep, emotional well-being, physical fitness, and migraine prevention in some individuals. However, exercise may aggravate symptoms during an ongoing attack, while new headaches specifically precipitated by exertion may require clinical assessment.

Behavioral interventions, including appropriate stress-management approaches, may be useful components of care. Their benefits should not be interpreted as evidence that migraine is caused by psychological weakness, poor self-control, or insufficient resilience.

The educational framework known as SEEDS—sleep, exercise, eating, diary, and stress—provides a practical way to organize lifestyle-related discussions in migraine care. Its value lies in helping people identify manageable aspects of daily life, not in suggesting that every migraine attack can be prevented through behavioral change.

For Lifestyle Medicine, the aim should be to support sustainable behaviors that may benefit health and migraine management without making patients feel responsible for identifying and eliminating every possible trigger.

When Acute Medication Use Becomes Part of the Problem

Medication-overuse headache is an important complication of recurrent headache disorders, particularly migraine.

A person may initially use medication only for occasional attacks. As headaches become more frequent, acute treatment is taken more often. Over time, increasing headache frequency and medication use may become closely linked, making it difficult to determine whether migraine is worsening, medication overuse is contributing, or both are occurring.

According to the International Classification of Headache Disorders, Third Edition, medication-overuse headache generally involves headache occurring on at least 15 days per month in someone with a pre-existing headache disorder, together with regular overuse of acute or symptomatic headache medication for more than three months.

The relevant threshold depends on the medication class. For triptans, ergot derivatives, opioids, and combination analgesics, the overuse threshold is generally ten or more days per month for more than three months. For non-opioid analgesics, including paracetamol and nonsteroidal anti-inflammatory drugs, it is generally 15 or more days per month over the same period.

Medication-overuse headache may also occur when several classes of acute medication are used on a combined total of at least ten days per month, even if no individual class exceeds its own threshold.

These thresholds concern days of medication use, not simply the number of tablets taken. Taking several doses on one day is different from taking medication on many separate days.

It is important to distinguish medication overuse from medication-overuse headache. Exceeding a medication-use threshold does not automatically establish the diagnosis. Headache frequency, duration of overuse, the underlying headache disorder, and other possible explanations must also be considered.

This distinction has become particularly relevant as newer migraine-specific treatments have emerged.

Gepants, which block calcitonin gene-related peptide receptors, do not appear to carry the same established medication-overuse headache risk associated with several traditional acute treatments. A review published in Headache in February 2026 discussed evidence from experimental studies, clinical trials, and preventive treatment experience suggesting that these medicines are unlikely to induce medication-overuse headache in the same way as some older treatments.

However, much of this conclusion is based on indirect evidence, and additional long-term clinical data remain valuable. The absence of an established medication-overuse headache risk should not be interpreted as permission for unrestricted use.

Frequent reliance on acute medication may indicate inadequate migraine control, even when formal medication-overuse criteria are not met. It should prompt consideration of whether the overall treatment plan remains appropriate.

The response to medication overuse should also be individualized. Simply telling every patient to stop taking pain medication may be ineffective or unsafe.

Management may involve education, reducing or withdrawing the overused medicine, and initiating or optimizing preventive treatment. The approach depends on the medications involved, headache frequency, coexisting conditions, and the patient's clinical circumstances.

Certain medicines, particularly opioids and barbiturate-containing preparations, may require supervised withdrawal because abrupt discontinuation can create additional risks.

The objective is not merely to reduce medication use. It is to improve migraine control while ensuring that patients have an effective and safe plan for treating individual attacks.

Preventive Treatment Should Not Wait Until Lifestyle Changes Have Failed

One of the most important messages from recent migraine guidance concerns when preventive treatment should be considered.

Acute treatment aims to relieve an attack after it begins. Preventive treatment aims to reduce migraine frequency and may also improve attack severity, disability, quality of life, and reliance on acute medication.

On August 31, 2026, the American Academy of Neurology and the American Headache Society published updated joint practice recommendations on pharmacological migraine prevention in adults.

The guideline recommends offering preventive treatment to adults with migraine who experience four or more migraine days per month, or four or more moderate-to-severe headache days per month. It also recommends offering preventive treatment when migraine causes substantial disability, even if these frequency thresholds are not met.

For Lifestyle Medicine, this has an important practical implication. A person experiencing frequent migraine should not automatically be advised to improve sleep, follow a restrictive diet, or manage stress for several months before preventive treatment is discussed. Lifestyle support can begin alongside appropriate medical treatment.

Similarly, someone experiencing fewer attacks but repeatedly missing work, being unable to care for family members, or having substantial difficulty completing ordinary activities may benefit from a discussion about prevention.

Offering preventive treatment does not mean every person meeting these criteria must receive medication. Treatment decisions should involve informed discussion of expected benefits, possible harms, available options, and the patient's preferences.

The updated guideline recognizes several evidence-supported preventive options, including established oral medications and newer treatments targeting calcitonin gene-related peptide pathways. OnabotulinumtoxinA is also an established preventive option for appropriately selected patients with chronic migraine.

Treatment selection involves more than choosing the newest medicine. Clinicians must consider other medical conditions, contraindications, adverse effects, medication interactions, previous treatment response, reproductive considerations, affordability, access, and patient preferences.

Some established preventive medicines have important safety limitations. Topiramate and valproate, for example, carry significant risks during pregnancy. The 2026 guideline emphasizes counseling people who may become pregnant about potential fetal risks and avoiding medicines with known teratogenic effects when possible.

Decisions regarding migraine prevention during pregnancy or when pregnancy is planned require particular care, including consideration of nonpharmacological approaches and individualized assessment of the benefits and risks of medication.

The existence of newer preventive treatments does not mean every patient should receive them or that all such medicines are authorized, available, or reimbursed in Viet Nam.

International recommendations must be interpreted alongside applicable Vietnamese professional requirements, the regulatory status of medicines, and individual clinical circumstances.

The 2026 guideline also recommends offering preventive medication to people with migraine who meet criteria for medication overuse or medication-overuse headache. This reinforces the importance of managing the underlying migraine rather than focusing exclusively on reducing acute medication use.

Preventive treatment requires appropriate follow-up. For most preventive medicines, the guideline recommends waiting at least eight to twelve weeks at a recommended, tolerated dose before assessing effectiveness. For onabotulinumtoxinA, it recommends a 24-week assessment period at the recommended dose.

These are general treatment-assessment recommendations rather than rigid rules for every patient. Earlier review, dose optimization, or treatment changes may be necessary because of adverse effects, poor tolerability, or other clinical considerations.

Effectiveness should be evaluated using headache frequency, severity, associated symptoms, disability, acute medication use, and the patient's goals.

Lifestyle Medicine and preventive medication should therefore be understood as complementary components of migraine care rather than competing alternatives.

A Headache Diary Can Support Better Clinical Decisions

A headache diary can provide a practical connection between daily experiences and clinical decision-making.

Patients may remember their most severe attacks but underestimate the number of days they experience headaches or how frequently they take medication. This becomes particularly difficult when symptoms fluctuate or several treatments are used.

A diary can help document headache days, migraine symptoms, attack severity, acute medication-use days, and the extent to which headaches interfere with work, study, family responsibilities, and other activities.

Sleep timing, menstrual patterns, missed meals, and suspected contributing factors may also be recorded when relevant. However, tracking every possible exposure is not necessary and can become burdensome.

The purpose is not to make patients monitor every detail of daily life or achieve a perfect record. It is to identify information that may improve diagnosis, treatment selection, and follow-up.

A diary may reveal that acute medication is being taken on more days than initially recognized. It may show increasing headache frequency or continuing disability despite attempts to improve lifestyle habits.

Standardized measures such as the Migraine Disability Assessment Scale and Headache Impact Test can provide additional information about migraine-related disability. These tools complement, rather than replace, a careful clinical history.

The International Headache Society's October 2026 publication on headache history-taking emphasizes the importance of structured assessment alongside communication that captures the patient's experience.

This is relevant when evaluating treatment success. A reduction in monthly headache days may be important, but so are the person's ability to work reliably, participate in family life, and maintain ordinary activities.

A useful treatment plan should therefore be guided by meaningful outcomes rather than headache frequency alone.

Applying International Migraine Evidence in Viet Nam

Migraine care in Viet Nam needs to account for evolving international evidence and the country's existing professional and regulatory framework.

On August 26, 2026, the Ministry of Health issued Decision No. 2730/QĐ-BYT, promulgating Volume III of the Guidelines for Diagnosis and Treatment Using Traditional Medicine and Integrating Traditional and Modern Medicine.

The document includes a section on migraine. Its modern-medicine content refers to the International Classification of Headache Disorders, recognizes medication-overuse headache, and discusses both acute and preventive treatment.

The preventive recommendations also include adequate sleep, relatively consistent sleep and wake times, appropriate physical activity, regular meals, hydration, and attention to possible triggering factors. Behavioral approaches such as cognitive behavioral therapy, biofeedback, and relaxation are also discussed within the treatment framework.

These elements create a connection with evidence-based Lifestyle Medicine. However, the decision must be understood within its stated purpose and professional scope.

It concerns diagnosis and treatment using traditional medicine and the integration of traditional and modern medicine. Its framework also includes traditional medicine interventions and recommendations regarding their integration with modern treatment.

It should not be presented as a dedicated national Lifestyle Medicine guideline or as evidence that every intervention mentioned has the same level of scientific support.

International clinical guidance provides additional perspectives that may be useful for professional education and practice.

The 2026 American Academy of Neurology and American Headache Society guideline emphasizes the role of preventive medication based on migraine frequency and disability. The International Headache Society's 2025 evidence-based guidelines also provide recommendations concerning acute and preventive pharmacological treatment.

These documents should be interpreted alongside applicable Vietnamese professional requirements rather than assumed to have automatic regulatory force.

Evidence from the wider Asia-Pacific region may also inform professional discussion.

A Delphi consensus study published in Frontiers in Neurology on May 28, 2026, involved 14 headache specialists from seven countries in the Asia-Pacific region. It examined the clinical application of migraine diagnostic criteria and treatment recommendations, including the use of newer migraine-specific therapies.

The study highlighted the importance of established diagnostic criteria, assessment of disability, and appropriate treatment selection. However, its findings reflect the opinions of a small selected expert group rather than a representative survey of clinical practice.

Viet Nam was not among the participating countries, so the results should not be interpreted as direct evidence of migraine management in Vietnamese healthcare facilities.

More locally relevant research would be valuable, particularly concerning migraine-related disability, acute medication-use patterns, access to preventive treatment, and the feasibility of integrating individualized lifestyle support into routine clinical care.

The appropriate approach in Viet Nam is not simply to reproduce an international treatment model. It is to combine reliable evidence with clinical judgment, locally applicable professional guidance, patient circumstances, and realistic access to care.

Treatment Plans Must Reflect the Patient's Circumstances

Migraine management does not take place independently of work, family responsibilities, financial circumstances, or access to healthcare.

Someone working rotating shifts may find regular sleep timing difficult to maintain. A person with limited income may struggle to attend repeated consultations or obtain certain medicines. Another may follow a healthy lifestyle but continue experiencing disabling attacks that require preventive treatment.

These circumstances should influence how management plans are developed.

A recommendation to maintain regular meals may be practical for one person but difficult for someone whose job does not allow predictable breaks. An expensive dietary program may offer little additional value when the person primarily needs accessible, balanced meals and an effective migraine treatment plan.

Likewise, repeated advice to avoid stress may not be helpful when the person's main difficulties involve demanding working hours, caregiving responsibilities, or inadequate migraine control.

For Lifestyle Medicine, individualization means more than adjusting behavior-change goals. It also requires recognizing which barriers can reasonably be addressed by the person and which may require clinical, workplace, family, or other forms of support.

This approach is consistent with the growing emphasis on social determinants of health in the 2025 update of the Lifestyle Medicine Core Competencies.

Migraine may remain disabling despite substantial efforts to maintain healthy routines. Care should acknowledge this reality while providing interventions supported by evidence and suited to the individual's circumstances.

The aim is not to make patients responsible for preventing every attack through perfect behavior. It is to help them manage a neurological condition through appropriate clinical care and sustainable daily practices.

Professional Responsibility and Patient Safety in Viet Nam

General migraine education may appropriately be provided through professional websites, educational resources, and other health-information activities. Explaining the possible benefits of healthy routines, the risks associated with frequent acute medication use, and the role of preventive treatment is different from diagnosing migraine or prescribing treatment for an individual.

In Viet Nam, clinical assessment, diagnosis, prescribing, and treatment are governed by the Law on Medical Examination and Treatment and applicable implementing regulations.

Consolidated Document No. 26/VBHN-VPQH, dated February 26, 2026, provides the consolidated legal text incorporating relevant amendments.

Healthcare professionals and facilities must operate within applicable licensing, professional qualification, and authorized scope-of-practice requirements.

Education or certification in Lifestyle Medicine does not independently authorize someone to diagnose neurological disease, prescribe migraine medication, or provide regulated healthcare services outside their lawful professional scope.

The same distinction applies when discussing specific medicines. Describing a treatment as evidence-supported in an international guideline does not constitute a recommendation for individual use or establish its regulatory approval, availability, or reimbursement status in Viet Nam.

People with persistent, worsening, atypical, or disabling headaches should receive appropriate clinical assessment. Sudden severe headache, new neurological deficits, altered consciousness, or other concerning features may require urgent evaluation to exclude serious secondary causes.

Privacy is also important when headache diaries, clinical histories, or patient experiences are collected, shared, or used in educational activities.

Viet Nam's Law on Personal Data Protection No. 91/2025/QH15, effective January 1, 2026, is relevant to the handling of identifiable personal health information. Clinical confidentiality and other applicable professional requirements must also be respected.

Patient examples used in educational materials should avoid unnecessary identifying details. Any use or disclosure of identifiable health information must have an appropriate lawful basis and comply with relevant professional obligations.

What This Means for the Vietnam Lifestyle Medicine Alliance

Migraine provides an example of both the contribution and limitations of evidence-based Lifestyle Medicine.

Sleep regularity, appropriate physical activity, balanced nutrition, adequate hydration, and stress-management approaches may support migraine care. However, these interventions should not replace accurate diagnosis, effective acute treatment, assessment of medication use, or preventive therapy when indicated.

For the Vietnam Lifestyle Medicine Alliance (VLMA), this provides an opportunity to support professional understanding of how lifestyle-related interventions fit within established neurological care.

Relevant educational topics could include the relationship between sleep and migraine, interpretation of suspected triggers, recognition of medication-overuse risk, appropriate use of headache diaries, and the importance of considering preventive treatment at the right time.

Such work may benefit from collaboration with appropriately qualified neurologists, headache specialists, primary care physicians, sleep medicine professionals, pharmacists, and other relevant practitioners.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. Its intended contribution is professional education, scientific knowledge exchange, capability development, and collaboration.

These potential educational activities do not mean that VLMA currently operates a migraine clinic, provides neurological consultations, prescribes medicines, or delivers individualized treatment.

Clinical assessment and management remain the responsibilities of appropriately authorized healthcare professionals and facilities.

Maintaining this distinction helps ensure that discussions of Lifestyle Medicine remain scientifically informed, clinically responsible, and appropriate to the Vietnamese healthcare context.

Better Migraine Care Requires More Than Better Habits

Migraine illustrates why lifestyle interventions should be considered within comprehensive clinical care rather than promoted as a separate solution.

For some people, improving sleep regularity or avoiding missed meals may be a useful part of management. Others may need a more effective acute treatment plan, assessment of frequent medication use, or preventive therapy to reduce recurrent disabling attacks.

These approaches can complement one another, but they are not interchangeable.

A person with frequent migraine should not have to demonstrate that lifestyle changes have failed before appropriate medical treatment is considered. Equally, prescribing medication does not remove the potential value of supporting healthier daily routines.

The most useful approach begins with understanding the individual's headache pattern, treatment history, health conditions, daily circumstances, and priorities. It continues through appropriate treatment, follow-up, and adjustment when the initial plan is insufficient.

For healthcare professionals in Viet Nam, responsible migraine care involves combining evidence-based clinical management with realistic lifestyle support while respecting relevant Vietnamese professional and legal requirements.

Healthy routines can support migraine management, but they should never become a reason to delay appropriate diagnosis, review excessive medication use, or postpone preventive treatment when it is indicated.

For VLMA, advancing this balanced understanding is one way to support the responsible integration of Lifestyle Medicine into clinical education and healthcare discussions in Viet Nam.

Selected References

1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, Third Edition. Cephalalgia. 2018;38(1):1–211. Includes diagnostic criteria for migraine and medication-overuse headache. DOI: 10.1177/0333102417738202.

2. Potrebic S, Tanveer S, Becker WJ, et al. Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the American Academy of Neurology Guidelines Subcommittee and the American Headache Society. Neurology. 2026;107(7). First published online August 31, 2026. DOI: 10.1212/WNL.0000000000214881.

3. Pringsheim T, Smith DB, Tanveer S, et al. Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the American Academy of Neurology Guidelines Subcommittee and the American Headache Society. Neurology. 2026;107(7). DOI: 10.1212/WNL.0000000000218112.

4. Ornello R, Caponnetto V, Ahmed F, et al. Evidence-Based Guidelines for the Pharmacological Treatment of Migraine. Cephalalgia. 2025;45(4). DOI: 10.1177/03331024241305381.

5. National Institute for Health and Care Excellence. Headaches in Over 12s: Diagnosis and Management. Clinical Guideline CG150. Originally published September 19, 2012. Updated June 3, 2025.

6. Robblee J, Starling AJ. SEEDS for Success: Lifestyle Management in Migraine. Cleveland Clinic Journal of Medicine. 2019;86(11):741–749. DOI: 10.3949/ccjm.86a.19009.

7. Vgontzas A, Fanning KM, Bostic RC, et al. The Association Between Sleep Duration and Migraine Frequency, Disability, and Perceived Stress in the Headache Assessment via a Digital Platform in United States Study. Headache. Published online September 28, 2026. DOI: 10.1111/head.70215.

8. Lipton RB, Dodick DW, Davis L, et al. Integrating Gepants Into Clinical Practice for the Acute Treatment of Migraine. Headache. 2026;66(4):976–989. DOI: 10.1111/head.70047.

9. Siow CHC, Yu S, Tanprawate S, et al. Delphi Consensus on the Real-World Application of the Updated Diagnostic and Treatment Guidelines for Migraine in Asia Pacific. Frontiers in Neurology. 2026;17:1770966. Published May 28, 2026. DOI: 10.3389/fneur.2026.1770966.

10. Souza MNP, Skorobogatykh K, Puledda F, et al. Optimizing Headache History-Taking: A Structured Approach From the International Headache Society Education Committee. Cephalalgia Reports. Published online October 21, 2026. DOI: 10.1177/25158163261486759.

11. Ministry of Health of Viet Nam. Decision No. 2730/QĐ-BYT Issuing the Guidelines for Diagnosis and Treatment Using Traditional Medicine and Integrating Traditional and Modern Medicine, Volume III. August 26, 2026.

12. Office of the National Assembly of Viet Nam. Consolidated Document No. 26/VBHN-VPQH: Law on Medical Examination and Treatment. February 26, 2026.

13. National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. June 26, 2025. Effective January 1, 2026.

14. Rea BL, Cheema S, Lanza S, et al. Lifestyle Medicine Core Competencies: 2025 Update. American Journal of Lifestyle Medicine. 2026;20(3):443–451. First published online October 28, 2025. DOI: 10.1177/15598276251379821.

Editorial and Professional Scope Note

This article presents an educational and professional perspective of the Vietnam Lifestyle Medicine Alliance on the contribution and limitations of evidence-based Lifestyle Medicine in migraine care, based on information reviewed through October 30, 2026. It is intended for professional education, scientific knowledge exchange, and general information.

The article does not constitute a clinical practice guideline, individualized medical advice, a neurological diagnosis, a medication prescription, or a treatment protocol. It does not recommend that any individual initiate, discontinue, or change prescribed treatment without appropriate professional assessment and supervision.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. It is not a licensed medical examination or treatment facility and does not independently provide migraine consultations, neurological examinations, individualized migraine treatment, or medication prescribing services.

Clinical assessment, diagnosis, prescription, treatment, and follow-up must be undertaken by appropriately authorized healthcare professionals and facilities within their lawful professional scopes, taking account of individual clinical circumstances, applicable Vietnamese professional guidance, relevant scientific evidence, and legal requirements.

References to international guidelines, medications, and treatment options are provided for educational purposes. Their inclusion does not establish regulatory approval, clinical availability, or reimbursement in Viet Nam, nor does it imply that VLMA has formally adopted, validated, or implemented the interventions discussed.

Lifestyle-related interventions should not delay or replace necessary clinical assessment, appropriate acute or preventive treatment, investigation of concerning headache symptoms, or specialist care when indicated.